Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | SNK01 |
| Synonyms | |
| Therapy Description |
SNK01 is a modified autologous natural killer cell therapy, which potentially increases cytotoxicity against tumor cells (J. of Clin. Onc. 2020 38:15_suppl, e15024). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| SNK01 | SNK-01|SNK 01 | SNK01 is a modified autologous natural killer cell therapy, which potentially increases cytotoxicity against tumor cells (J. of Clin. Onc. 2020 38:15_suppl, e15024). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03941262 | Phase I | Avelumab + SNK01 SNK01 Pembrolizumab + SNK01 | Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy | Completed | USA | 0 |